Umeclidinium bromide
Chemical compound
- US DailyMed: Umeclidinium bromide
administration
- R03BB07 (WHO)
R03AL03 (WHO) (+vilanterol)
- Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
- 869113-09-7
- 11519069
- 9693857
- 7AN603V4JV
- D10181
- CHEBI:79040
- DTXSID50235966
- Interactive image
- OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]
- InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
- Key:PEJHHXHHNGORMP-UHFFFAOYSA-M
Umeclidinium bromide, sold under the brand name Incruse Ellipta, is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[3] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol)[4][5] and also as a triple-therapy combination as fluticasone furoate/umeclidinium bromide/vilanterol.[6]
It is on the World Health Organization's List of Essential Medicines.[7] In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[8][9]
References
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2014". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
- ^ a b "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.
- ^ Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
- ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
- ^ "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Retrieved 11 July 2020.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
- ^ "Umeclidinium - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
- v
- t
- e
| Short-acting β2 agonists | |
|---|---|
| Long-acting β2 agonists |
|
| Ultra-long-acting β2 agonists | |
| Other |
muscarinic antagonist
- Aclidinium bromide
- Glycopyrronium bromide
- Ipratropium bromide#
- Oxitropium bromide
- Tiotropium bromide
- Umeclidinium bromide
| Leukotriene antagonists | |
|---|---|
| Arachidonate 5-lipoxygenase inhibitors | |
| Thromboxane receptor antagonists | |
| Non-xanthine PDE4 inhibitors |
- Aclidinium bromide/formoterol
- Beclometasone/formoterol
- Beclometasone/formoterol/glycopyrronium bromide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Fluticasone furoate/umeclidinium bromide/vilanterol
- Fluticasone furoate/vilanterol
- Fluticasone propionate/salmeterol
- Glycopyrronium bromide/formoterol
- Indacaterol/glycopyrronium bromide
- Indacaterol/glycopyrronium bromide/mometasone
- Indacaterol/mometasone
- Ipratropium bromide/salbutamol
- Mometasone/formoterol
- Salbutamol (albuterol)/budesonide
- Umeclidinium bromide/vilanterol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subsidiaries |
| ||||||||
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
| |||||||||
Portal:
Medicine
 | This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
